Handelsbanken Fonder’s Teva Pharmaceuticals TEVA Stock Holding History

Handelsbanken Fonder’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$445K	Hold	13,138	–	–	﹤0.01%	1397
2026 Q1	$396K	Hold	13,138	–	–	﹤0.01%	1358
2025 Q4	$410K	Hold	13,138	–	–	﹤0.01%	1365
2025 Q3	$265K	Sell	13,138 -2,654	-17%	-$46.6K	﹤0.01%	1443
2025 Q2	$265K	Hold	15,792	–	–	﹤0.01%	1450
2025 Q1	$243K	Buy	+15,792	New	+$282K	﹤0.01%	1459
2022 Q2	–	Sell	-26,500	Closed	-$249K	–	1691
2022 Q1	$249K	Hold	26,500	–	–	﹤0.01%	1581
2021 Q4	$212K	Hold	26,500	–	–	﹤0.01%	1690
2021 Q3	$258K	Hold	26,500	–	–	﹤0.01%	1621
2021 Q2	$262K	Hold	26,500	–	–	﹤0.01%	1664
2021 Q1	$306K	Sell	26,500 -2,200	-8%	-$25.2K	﹤0.01%	1435
2020 Q4	$277K	Hold	28,700	–	–	﹤0.01%	1438
2020 Q3	$259K	Hold	28,700	–	–	﹤0.01%	1305
2020 Q2	$354K	Buy	+28,700	New	+$325K	﹤0.01%	1128
2019 Q1	–	Sell	-45,000	Closed	-$694K	–	190
2018 Q4	$694K	Buy	45,000 +22,500	+100%	+$461K	0.01%	165
2018 Q3	$485K	Buy	+22,500	New	+$522K	0.01%	176

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Handelsbanken Fonder's TEVA Position: Q2 2026 in Review

Handelsbanken Fonder held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 13,138 shares worth $445K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

Handelsbanken Fonder first reported a position in TEVA in Q3 2018 and has held it in 16 quarters since. The position peaked at $694K in Q4 2018. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Handelsbanken Fonder held 13,138 shares of Teva Pharmaceuticals worth $445K as of Q2 2026.
Handelsbanken Fonder left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #1397 holding.
Handelsbanken Fonder first reported a position in Teva Pharmaceuticals in Q3 2018 and has held it in 16 quarters since.
Handelsbanken Fonder's Teva Pharmaceuticals position peaked at $694K in Q4 2018.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.